Prosecution Insights
Prosecution Insights
Technology area: Medical Devices & Mechanical Engineering
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Pacific Diabetes Technologies Inc. is currently navigating 2 pending office actions in the Medical Devices & Mechanical Engineering technology area. This level of activity reflects a focused prosecution phase for the company's patent applications. The firm is actively responding to these actions to secure its mechanical and medical innovations.
The company's applications are being reviewed by 2 distinct examiners across 2 distinct art units. This indicates that the portfolio covers different technical aspects that require evaluation by separate specialized departments. With 2 distinct examiners, the company must manage two separate dialogues, each tailored to the specific requirements of the individual examiner and their respective art unit.
NICHOLS, CHARLES W is the busiest examiner for the portfolio. This examiner is currently managing 1 busiest examiner pending office action. Because there are 2 pending office actions in total, NICHOLS, CHARLES W is responsible for a portion of the active workload. Practitioners should be prepared to address the specific concerns of NICHOLS, CHARLES W while simultaneously managing the other pending matter with a different examiner.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NICHOLS, CHARLES W | 1 | 56.0% | +54.1% |
| MARMOR II, CHARLES ALAN | 1 | 12.4% | +25.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18132589 | Drug Delivery Cannula with Continuous Glucose Monitoring Capability | MARMOR II, CHARLES ALAN | 33d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18132589 | Drug Delivery Cannula with Continuous Glucose Monitoring Capability | MARMOR II, CHARLES ALAN | 33d |
| 18227071 | PUMP-CONNECTABLE ANALYTE SENSING CANNULA | NICHOLS, CHARLES W | — |
| Art Unit | Apps |
|---|---|
| 3783 | 1 |
| 3791 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18227071 | PUMP-CONNECTABLE ANALYTE SENSING CANNULA | NICHOLS, CHARLES W | 3783 | §103 | Non-Final OA | — | Pending | Jul 27, 2023 |
| 18132589 | Drug Delivery Cannula with Continuous Glucose Monitoring Capability | MARMOR II, CHARLES ALAN | 3791 | §103 | Final Rejection | 33d | Pending | Apr 10, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial